- Home
- CUE vs ACET Comparison
CUE vs ACET Comparison
Compare CUE & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- ACET
- Stock Information
- Founded
- CUE 2014
- ACET 1947
- Country
- CUE United States
- ACET United States
- Employees
- CUE N/A
- ACET N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- ACET Health Care
- Exchange
- CUE Nasdaq
- ACET Nasdaq
- Market Cap
- CUE 57.7M
- ACET 63.8M
- IPO Year
- CUE 2018
- ACET N/A
- Fundamental
- Price
- CUE $0.74
- ACET $0.67
- Analyst Decision
- CUE Strong Buy
- ACET Strong Buy
- Analyst Count
- CUE 3
- ACET 7
- Target Price
- CUE $3.00
- ACET $5.60
- AVG Volume (30 Days)
- CUE 510.6K
- ACET 363.0K
- Earning Date
- CUE 08-13-2025
- ACET 08-12-2025
- Dividend Yield
- CUE N/A
- ACET N/A
- EPS Growth
- CUE N/A
- ACET N/A
- EPS
- CUE N/A
- ACET N/A
- Revenue
- CUE $7,991,000.00
- ACET N/A
- Revenue This Year
- CUE N/A
- ACET N/A
- Revenue Next Year
- CUE $23.84
- ACET N/A
- P/E Ratio
- CUE N/A
- ACET N/A
- Revenue Growth
- CUE 13.83
- ACET N/A
- 52 Week Low
- CUE $0.45
- ACET $0.45
- 52 Week High
- CUE $1.99
- ACET $1.64
- Technical
- Relative Strength Index (RSI)
- CUE 43.63
- ACET 41.56
- Support Level
- CUE $0.84
- ACET $0.68
- Resistance Level
- CUE $0.90
- ACET $0.82
- Average True Range (ATR)
- CUE 0.10
- ACET 0.05
- MACD
- CUE -0.02
- ACET -0.01
- Stochastic Oscillator
- CUE 11.27
- ACET 6.57
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.